PJPatrick G. Johnston

Patrick G. Johnston

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patrick G. Johnston has a total of 129 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    FLIP(L) determines p53 induced life or death

    by Andrea Lees, Alexander J. McIntyre, Fiammetta Falcone, Nyree T. Crawford, Christopher McCann, Gerard P. Quinn, Jamie Z. Roberts, Tamas Sessler, Peter F. Gallagher, Gemma M.A. Gregg, et al.

    How p53 differentially activates cell cycle arrest versus cell death remains poorly understood. Here, we demonstrate that upregulation of canonical pro-apoptotic p53 target genes in colon cancer cells imposes a critical dependence on the long splice form of the caspase-8 regulator FLIP (FLIP(L)), which we identify as a direct p53 transcriptional target. Inhibiting FLIP(L) expression with siRNA or Class-I HDAC inhibitors promotes apoptosis in response to p53 activation by the MDM2 inhibitor Nutlin-3A, which otherwise predominantly induces cell-cycle arrest. When FLIP(L) upregulation is inhibited, apoptosis is induced in response to p53 activation via a novel ligand-independent TRAIL-R2/caspase-8 complex, which, by activating BID, induces mitochondrial-mediated apoptosis. Notably, FLIP(L) depletion inhibits p53-induced expression of the cell cycle regulator p21 and enhances p53-mediated upregulation of PUMA, with the latter activating mitochondrial-mediated apoptosis in FLIP(L)-depleted, Nutlin-3A-treated cells lacking TRAIL-R2/caspase-8. Thus, we report two previously undescribed, novel FLIP(L)-dependent mechanisms that determine cell fate following p53 activation.


  • Open Access

    Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF -mutant stage II and III colon cancer

    by Philip D. Dunne, Helen G. Coleman, Peter Bankhead, Matthew Alderdice, Ronan T. Gray, Stephena McQuaid, Victoria Bingham, Maurice B. Loughrey, Jacqueline A. James, Amy M. B. McCorry, et al.

    Background: BRAF mutation occurs in 8-15% of colon cancers (CC), and is associated with poor prognosis in metastatic disease. Compared to wild-type BRAF ( BRAFWT ) disease, stage II/III CC patients with BRAF mutant ( BRAFMT ) tumors have shorter overall survival after relapse; however, time-to-relapse is not significantly different. The aim of this investigation was to identify, and validate, novel predictors of relapse of stage II/III BRAFMT CC. Patients and methods: We used gene expression data from a cohort of 460 patients (GSE39582) to perform a supervised classification analysis based on risk-of-relapse within BRAFMT stage II/III CC, to identify transcriptomic biomarkers associated with prognosis within this genotype. These findings were validated using immunohistochemistry in an independent population-based cohort of Stage II/III CC (n=691), applying Cox proportional hazards analysis to determine associations with survival. Results: High gene expression levels of Bcl-xL, a key regulator of apoptosis, were associated with increased risk of relapse, specifically in BRAFMT tumors (HR=8.3, 95% CI 1.7-41.7), but not KRASMT/BRAFWT or KRASWT/BRAFWT tumors. High Bcl-xL protein expression in BRAFMT , untreated, stage II/III CC was confirmed to be associated with an increased risk of death in an independent cohort (HR=12.13, 95% CI 2.49-59.13). Additionally, BRAFMT tumors with high levels of Bcl-xL protein expression appeared to benefit from adjuvant chemotherapy (P for interaction =0.006), indicating the potential predictive value of Bcl-xL expression in this setting. Conclusions: These findings provide evidence that Bcl-xL gene and/or protein expression identifies a poor prognostic subgroup of BRAFMT stage II/III CC patients, who may benefit from adjuvant chemotherapy. Key Message: Using a combination of computational biology discovery and immunohistochemistry validation in independent patient cohorts, we show that high expression of the apoptosis regulator Bcl-xL is associated with disease relapse specifically within BRAF mutant stage II/III colon cancer. This data could enable tailored disease management to reduce relapse rates in the most aggressive subtype.


  • A systems model of BCL-2 dependent apoptosis to predict stage II CRC patients benefiting from adjuvant chemotherapy and as a prognostic tool for stage III CRC patients with increased risk of recurrence.

    by Jochen Prehn, Andreas Ulrich Lindner, Manuela Salvucci, Mattia Cremona, Naser Monsefi, Sarah Curry, Clare Morgan, Alexa Resler, Robert O'Byrne, Orna Bacon, et al.

    3584 Background: Over the past decades the TNM staging system has remained the best indicator for the clinical outcome of CRC patients, and it is used to stratify patients for adjuvant chemotherapy after surgical resection of the tumor. Currently, adjuvant chemotherapy is not recommended for stage II patients. Previously, we developed a systems model of the BCL2 family of proteins (DR_MOMP) to assess cancer cells’ resistance to induce mitochondrial outer membrane permeabilization (MOMP), based on absolute protein levels and the interaction of pro- and anti-apoptotic BCL2 family proteins. Methods: Reverse Phase Protein Arrays (RPPA) were used to determine BAK, BAX, BCL2, BCL(X)L and MCL1 protein levels in primary tumours collected from two distinct cohorts: 1) 138 stage II CRC patients from a completed clinical trial, randomised to adjuvant 5-FU-based chemotherapy or observation only, 2) 128 stage III CRC patients treated with adjuvant 5-FU-based chemotherapy. DR_MOMP was employed to calculate the amount of cellular stress required to induce MOMP based on tumour protein levels. Protein level (RPPA) and mRNA expression (SeqV2 RSEM) data from the TCGA COAD cohort was used to validate the findings. Results: 1) Stage II patients randomised to observation only and classified as high-risk by DR_MOMP had an approximately 2-fold increased risk of death compared to patients receiving chemotherapy or classified as low-risk (HR 2.4; 95% CI 1.2-4.8; p-value = 0.02). 2) Stage III patients treated with chemotherapy and classified as high-risk had a more than 10-fold increased risk of death compared to low-risk patients (HR 10.6; 95% CI 2.4-46.3; p-value < 0.0001). The hazard ratio (HR) was similar in 261 stage II-IV patients of the TCGA COAD cohort (HR 10.6; 95% CI 1.2-12.5; p-value = 0.01). Conclusions: Our system holds promise as a novel predictive biomarker to stratify stage II CRC patients for adjuvant chemotherapy and as a prognostic biomarker for stage III patients. It could be combined with traditional staging to assess risk and in subsequent clinical management of patients.

  • Open Access

    ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer

    by Sandra Van Schaeybroeck, Murugan Kalimutho, Philip D. Dunne, Robbie Carson, Wendy Allen, Puthen V. Jithesh, Keara L. Redmond, Takehiko Sasazuki, Senji Shirasawa, Jaine Blayney, et al.


  • Open Access

    Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer

    by R C Turkington, D B Longley, W L Allen, L Stevenson, K McLaughlin, P D Dunne, J K Blayney, M Salto-Tellez, S Van Schaeybroeck, P G Johnston

    The discovery of underlying mechanisms of drug resistance, and the development of novel agents to target these pathways, is a priority for patients with advanced colorectal cancer (CRC). We previously undertook a systems biology approach to design a functional genomic screen and identified fibroblast growth factor receptor 4 (FGFR4) as a potential mediator of drug resistance. The aim of this study was to examine the role of FGFR4 in drug resistance using RNAi and the small-molecule inhibitor BGJ398 (Novartis). We found that FGFR4 is highly expressed at the RNA and protein levels in colon cancer tumour tissue compared with normal colonic mucosa and other tumours. Silencing of FGFR4 reduced cell viability in a panel of colon cancer cell lines and increased caspase-dependent apoptosis. A synergistic interaction was also observed between FGFR4 silencing and 5-fluorouracil (5-FU) and oxaliplatin chemotherapy in colon cancer cell lines. Mechanistically, FGFR4 silencing decreased activity of the pro-survival STAT3 transcription factor and expression of the anti-apoptotic protein c-FLIP. Furthermore, silencing of STAT3 resulted in downregulation of c-FLIP protein expression, suggesting that FGFR4 may regulate c-FLIP expression via STAT3. A similar phenotype and downstream pathway changes were observed following FGFR4 silencing in cell lines resistant to 5-FU, oxaliplatin and SN38 and upon exposure of parental cells to the FGFR small-molecule inhibitor BGJ398. Our results indicate that FGFR4 is a targetable regulator of chemo-resistance in CRC, and hence inhibiting FGFR4 in combination with 5-FU and oxaliplatin is a potential therapeutic strategy for this disease.


  • Open Access

    Personalized Medicine: Does the Molecular Suit Fit?

    by Edison T. Liu, Patrick G. Johnston


  • Expert Opinion: Future Frontiers and Challenges in Cancer Medicine

    by Patrick G. Johnston, Mark Lawler

    This article is the first in a series in European Perspectives that will engage with the European Oncology community to identify the ways in which the aspiration for enhanced standard of care for the cancer patient can be realized.


  • The High Tide of Cancer Research in Europe

    by Patrick G. Johnston, H.M. Pinedo

    The launch of the European edition of The Oncologist is announced.


  • Open Access

    Oncogenic Kras Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM17

    by Sandra Van Schaeybroeck, Joan N. Kyula, Audrey Fenton, Catherine S. Fenning, Takehiko Sasazuki, Senji Shirasawa, Daniel B. Longley, Patrick G. Johnston

    Oncogenic mutations in Kras occur in 40% to 45% of patients with advanced colorectal cancer (CRC). We have previously shown that chemotherapy acutely activates ADAM17, resulting in growth factor shedding, growth factor receptor activation, and drug resistance in CRC tumors. In this study, we examined the role of mutant Kras in regulating growth factor shedding and ADAM17 activity, using isogenic Kras mutant (MT) and wild-type (WT) HCT116 CRC cells. Significantly higher levels of TGF-α and VEGF were shed from KrasMT HCT116 cells, both basally and following chemotherapy treatment, and this correlated with increased pErk (phosphorylated extracellular signal regulated kinase)1/2 levels and ADAM17 activity. Inhibition of Kras, MEK (MAP/ERK kinase)1/2, or Erk1/2 inhibition abrogated chemotherapy-induced ADAM17 activity and TGF-α shedding. Moreover, we found that these effects were not drug or cell line specific. In addition, MEK1/2 inhibition in KrasMT xenografts resulted in significant decreases in ADAM17 activity and growth factor shedding in vivo, which correlated with dramatically attenuated tumor growth. Furthermore, we found that MEK1/2 inhibition significantly induced apoptosis both alone and when combined with chemotherapy in KrasMT cells. Importantly, we found that sensitivity to MEK1/2 inhibition was ADAM17 dependent in vitro and in vivo. Collectively, our findings indicate that oncogenic Kras regulates ADAM17 activity and thereby growth factor ligand shedding in a MEK1/2/Erk1/2-dependent manner and that KrasMT CRC tumors are vulnerable to MEK1/2 inhibitors, at least in part, due to their dependency on ADAM17 activity. Cancer Res; 71(3); 1071–80. ©2010 AACR.


  • Open Access

    The Colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information

    by Wendy L Allen, Puthen V Jithesh, Gavin R Oliver, Irina Proutski, Daniel B Longley, Heinz-Josef Lenz, Vitali Proutski, Paul Harkin, Patrick G Johnston

    Background: To date, there are no clinically reliable predictive markers of response to the current treatment regimens for advanced colorectal cancer. The aim of the current study was to compare and assess the power of transcriptional profiling using a generic microarray and a disease-specific transcriptome-based microarray. We also examined the biological and clinical relevance of the disease-specific transcriptome. Methods: DNA microarray profiling was carried out on isogenic sensitive and 5-FU-resistant HCT116 colorectal cancer cell lines using the Affymetrix HG-U133 Plus2.0 array and the Almac Diagnostics Colorectal cancer disease specific Research tool. In addition, DNA microarray profiling was also carried out on pre-treatment metastatic colorectal cancer biopsies using the colorectal cancer disease specific Research tool. The two microarray platforms were compared based on detection of probesets and biological information. Results: The results demonstrated that the disease-specific transcriptome-based microarray was able to out-perform the generic genomic-based microarray on a number of levels including detection of transcripts and pathway analysis. In addition, the disease-specific microarray contains a high percentage of antisense transcripts and further analysis demonstrated that a number of these exist in sense:antisense pairs. Comparison between cell line models and metastatic CRC patient biopsies further demonstrated that a number of the identified sense:antisense pairs were also detected in CRC patient biopsies, suggesting potential clinical relevance. Conclusions: Analysis from our in vitro and clinical experiments has demonstrated that many transcripts exist in sense:antisense pairs including IGF2BP2, which may have a direct regulatory function in the context of colorectal cancer. While the functional relevance of the antisense transcripts has been established by many studies, their functional role is currently unclear; however, the numbers that have been detected by the disease-specific microarray would suggest that they may be important regulatory transcripts. This study has demonstrated the power of a disease-specific transcriptome-based approach and highlighted the potential novel biologically and clinically relevant information that is gained when using such a methodology.